Sugi Predict

Sugi Predict / Targets / FLT3

FLT3

Receptor-type tyrosine-protein kinase FLT3 · P36888 · FLT3 on Sugi Atlas →

460,375 patent compounds predicted against FLT3, 313,418 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL57288 SCHEMBL57288 0.46 10/20
SCHEMBL58735 SCHEMBL58735 0.54 9/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.59 8/20
Zearalenone Zearalenone (SCHEMBL33754) 0.59 8/20
Zearalenone Zearalenone (SCHEMBL33755) 0.59 8/20
SCHEMBL59547 SCHEMBL59547 0.55 8/20
SCHEMBL58935 SCHEMBL58935 0.52 8/20
SCHEMBL58915 SCHEMBL58915 0.52 8/20
SCHEMBL57297 SCHEMBL57297 0.50 8/20
SCHEMBL59916 SCHEMBL59916 0.50 8/20
SCHEMBL59733 SCHEMBL59733 0.49 8/20
SCHEMBL59783 SCHEMBL59783 0.48 8/20
SCHEMBL58355 SCHEMBL58355 0.47 8/20
SCHEMBL59320 SCHEMBL59320 0.46 8/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL59541) 0.46 8/20
SCHEMBL58124 SCHEMBL58124 0.62 7/20
SCHEMBL58313 SCHEMBL58313 0.59 7/20
SCHEMBL57826 SCHEMBL57826 0.59 7/20
SCHEMBL57834 SCHEMBL57834 0.58 7/20
SCHEMBL58543 SCHEMBL58543 0.57 7/20

Clinical trials — most relevant to FLT3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
flt3L in Treating Patients With Acute Myeloid Leukemia PHASE3COMPLETED
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML PHASE2/PHASE3UNKNOWN
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia PHASE2/PHASE3UNKNOWN
FLT3-ITD Targeted Therapy in Fit AML Patients PHASE2/PHASE3NOT_YET_RECRUITING
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) PHASE3NOT_YET_RECRUITING
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML PHASE3COMPLETED
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML PHASE2COMPLETED
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD PHASE2UNKNOWN
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD PHASE2COMPLETED
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations PHASE2COMPLETED
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia PHASE2RECRUITING
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) PHASE2COMPLETED
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia PHASE1/PHASE2COMPLETED
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia PHASE2RECRUITING
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) PHASE1/PHASE2RECRUITING
Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD PHASE2COMPLETED
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients PHASE2UNKNOWN
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML PHASE2UNKNOWN
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) PHASE1UNKNOWN
AC220 for Children With Relapsed/Refractory ALL or AML PHASE1COMPLETED
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) PHASE1RECRUITING
TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia EARLY_PHASE1UNKNOWN
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. nanUNKNOWN
Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia nanCOMPLETED
FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia nanCOMPLETED
Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FLT3 binder may also engage these)

ProteinNameSimilarity
Q00342 — 1.000 Q00342 →
P26619 — 0.995 P26619 →
Q8AXC7 — 0.994 Q8AXC7 →
Q28889 — 0.994 Q28889 →
Q00495 — 0.994 Q00495 →
Q91909 — 0.994 Q91909 →
P43481 — 0.993 P43481 →
Q2HWD6 — 0.993 Q2HWD6 →
Q28317 — 0.993 Q28317 →
Q8UVR8 — 0.993 Q8UVR8 →
Q9I8N6 — 0.992 Q9I8N6 →
Q76II0 — 0.992 Q76II0 →
Q08156 — 0.992 Q08156 →
P79750 — 0.991 P79750 →
Q8JFR5 — 0.991 Q8JFR5 →
Q9PUF6 — 0.990 Q9PUF6 →
D2IYS2 — 0.990 D2IYS2 →
P79749 — 0.990 P79749 →
P18475 — 0.990 P18475 →
Q9DE49 — 0.990 Q9DE49 →
P35546 — 0.990 P35546 →
PDGFRA Platelet-derived growth factor receptor alpha 0.989 landscape →
P05532 — 0.989 P05532 →
P42159 — 0.989 P42159 →
G5ED65 — 0.989 G5ED65 →
P52583 — 0.989 P52583 →
P26618 — 0.989 P26618 →
Q29000 — 0.988 Q29000 →
Q07407 — 0.988 Q07407 →
P09581 — 0.988 P09581 →